# OnCo record gemtuzumab-ozogamicin (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/gemtuzumab-ozogamicin/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "gemtuzumab-ozogamicin" ;
  schema:name "Gemtuzumab ozogamicin"@en ;
  schema:description "Gemtuzumab ozogamicin (Mylotarg) is an anti-CD33 antibody linked to the DNA-cutting payload calicheamicin, the first ADC approved, in 2000 for relapsed acute myeloid leukaemia. An unstable linker and no benefit in a confirmatory trial led to withdrawal in 2010; it returned in 2017 at a lower fractionated dose, with liver toxicity, including veno-occlusive disease, its defining risk."@en ;
  schema:url <https://onco.cc/drugs/gemtuzumab-ozogamicin/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Gemtuzumab_ozogamicin> ;
  owl:sameAs <http://www.wikidata.org/entity/Q412685> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Gemtuzumab%20ozogamicin> ;
  onco:status "approved" ;
  onco:modality "ADC" ;
  schema:alternateName "Mylotarg" ;
  onco:approval "US 2000: Relapsed CD33+ AML (withdrawn 2010)", "US 2017: Newly diagnosed and relapsed CD33+ AML" ;
  onco:acceleratedApproval "US 2000-05-17: For patients with CD33+ AML in first relapse 60 years of age or older and not candidates for cytotoxic chemotherapy" ;
  onco:related <https://onco.cc/biomarkers/cd33-expression/> ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/aml-paediatric/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/cd33/> ;
  onco:companies <https://onco.cc/companies/pfizer/> ;
  onco:terms <https://onco.cc/terms/hydrazone/> ;
  onco:trials <https://onco.cc/trials/aaml0531/> .